Mifepristone (RU486) alone or in combination with a prostaglandin analogue for termination of early pregnancy: a review.
The availability of a medical mode of termination of early pregnancy by the administration of RU486, an antiprogesterone alone, or in combination with one of the PG analogues significantly reduces the maternal morbidity and mortality associated with the classical surgical abortion. RU486 given alone in early pregnancy induces complete abortion in 60% to 85% of cases, and when combined with prostaglandin analogues, gemeprost or sulprostone, reaches a success rate of 95% to 99%. RU486 may also be of potential value in the medical treatment of ectopic pregnancy. Its use as a postcoital contraception is suggested, but further research is required to determine whether RU486 can be used on a once-a-month basis for contraception.
Avrech
O M
OM
Department of Obstetrics and Gynecology, Assaf Harofeh Medical Center, Zerifin, Israel.
Golan
A
A
Weinraub
Z
Z
Bukovsky
I
I
Caspi
E
E
D000028:Abortion, Induced; D000302:Adrenal Cortex / Q000187:drug effects / Q000502:physiology; D000818:Animals; D003281:Contraceptives, Postcoital; D004338:Drug Combinations; D004717:Endometrium / Q000187:drug effects; D005260:Female; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D015735:Mifepristone / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D010053:Ovary / Q000187:drug effects; D011247:Pregnancy / Q000187:drug effects; D011453:Prostaglandins / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology
D003281:Contraceptives, Postcoital; D004338:Drug Combinations; D011453:Prostaglandins; D015735:Mifepristone